Echocardiographic Evaluation of Left Ventricular Hypertrophy

Weber, Michael A.; Drayer, Jan I.M.; Baird, Walter M.

doi:10.1097/00005344-198608003-00014

Cited by 23 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9798 Methyldopa, a drug that acts in a very similar way to clonidine, has also been demonstrated to induce regression of left ventricular hypertrophy. 97 I am just not sure that sufficient studies with clonidine have been conducted to conclusively settle that issue.…”

Section: Questions and Answersmentioning

confidence: 99%

Optimizing cardiovascular risk reduction during antihypertensive therapy.

Weinberger

1990

Hypertension

View full text Add to dashboard Cite

Section: Questions and Answersmentioning

confidence: 99%

Optimizing cardiovascular risk reduction during antihypertensive therapy.

Weinberger

1990

Hypertension

View full text Add to dashboard Cite

“…This finding also mimics observations made in human hypertensive subjects, a substantial proportion of which may show no clinical signs of left ventricular hypertrophy. 48 However, microscopic examination of the myocardial tissue revealed a modest but significant increase in cardiocyte transversal diameter at 10 months of age, with a large degree of overlapping between groups, as shown in Figures 4 and 5. Moreover, focal myocardial fibrosis was clearly seen and quantified at this phase.…”

Section: Discussionmentioning

confidence: 87%

Programmed hypertension in rats treated with a NF-κB inhibitor during nephrogenesis: renal mechanisms

et al. 2011

View full text Add to dashboard Cite

Suppression of the renin-angiotensin system (RAS) during murine lactation causes progressive renal injury, indicating a physiological action of angiotensin II on nephrogenesis. The nuclear factor NF-jB system is one of the main intracellular mediators of angiotensin II. We investigated whether inhibition of this system with pyrrolidine dithiocarbamate (PDTC) during rat nephrogenesis would lead to similar hypertension and renal injury as observed with RAS suppressors. Immediately after delivery, 32 Munich-Wistar dams, each nursing 6 male pups, were divided into 2 groups: C, untreated, and PDTC, receiving PDTC, 280 mg kg -1 day -1 orally, during 21 days. After weaning, the offspring were followed until 10 months of age without treatment. Adult rats that received neonatal PDTC exhibited stable hypertension and myocardial injury, without albuminuria. To gain additional insight into this process, the renal expression of RAS components and sodium transporters were determined by quantitative real-time PCR (qRT-PCR) at 3 and 10 months of life. Renal renin and angiotensinogen were upregulated at 3 and downregulated at 10 months of age, suggesting a role for early local RAS activation. Likewise, there was early upregulation of the proximal sodium/glucose and sodium/bicarbonate transporters, which abated later in life, suggesting that additional factors sustained hypertension in the long run. The conclusions drawn from the findings were as follows: (1) an intact NF-jB system during nephrogenesis may be essential to normal renal and cardiovascular function in adult life; (2) neonatal PDTC represents a new model of hypertension, lacking overt structural injury or functional impairment of the kidneys; and (3) hypertension in this model seems associated with early temporary activation of renal RAS and sodium transporters.

show abstract

“…Therapy should thus be aimed ar the specific mechanism causing the hypenrophy. 58 For patients with severe hypenension, high blood pressure is the predominant force causing hypenrophic changes, and any agent having antihypenensive effects should produce LVH regression. In a patient with mild to moderate hypenension, sympathetic drive may be the dominant factor causing the hypenrophy, so a sympatholytic agent may be necessary to reduce left ventricular size.…”

Section: Antihypertensive Agents Andlvhmentioning

confidence: 99%

Antihypertensive therapy

Harper

Forker²

1992

Postgraduate Medicine

View full text Add to dashboard Cite

Choosing antihypertensive agents that protect patients against cardiovascular and other complications is a growing trend in the treatment of mild to moderate hypertension. Calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors are favored because they have neutral or positive effects on lipid levels and insulin resistance. The alpha 1 blockers, especially doxazosin mesylate (Cardura), are enjoying a resurgence in popularity because they have a beneficial effect on lipid levels. In terms of preserving patients' quality of life, the ACE inhibitors in particular have been shown to have a positive impact. It has been shown that systolic hypertension in elderly patients should definitely be treated, but the most appropriate agent has yet to be defined. Therapy should be tailored to the individual. The following questions should be considered when choosing an antihypertensive agent: (1) What are its side effects (especially metabolic ones)? (2) Does it require only once- or twice-a-day dosing? (3) Does it cause regression of left ventricular hypertrophy? (4) Does it prevent death from coronary artery disease? (5) How will it affect quality of life? (6) How much does it cost? The goal of therapy should be to provide adequate blood pressure control throughout the day, enhance compliance, and protect the heart, brain, and kidneys without adversely affecting metabolic state.

show abstract

Echocardiographic Evaluation of Left Ventricular Hypertrophy

Cited by 23 publications

References 0 publications

Optimizing cardiovascular risk reduction during antihypertensive therapy.

Optimizing cardiovascular risk reduction during antihypertensive therapy.

Programmed hypertension in rats treated with a NF-κB inhibitor during nephrogenesis: renal mechanisms

Antihypertensive therapy

Contact Info

Product

Resources

About